Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod

After regulatory delays and manufacturing issues caused Bristol Myers Squibb investors to miss out on the lucrative Celgene contingent value right, the closely watched CAR-T drug liso-cel has finally scored an FDA nod.